These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 8174796)
1. At what stage should virus inactivation be carried out? Dorner F; Barrett PN; Eibl J Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796 [TBL] [Abstract][Full Text] [Related]
2. Theoretical considerations on viral inactivation or elimination. Willkommen H; Löwer J Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793 [No Abstract] [Full Text] [Related]
3. Considerations in performing virus spiking experiments and process validation studies. Darling AJ Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806 [TBL] [Abstract][Full Text] [Related]
4. Viral safety of solvent-detergent treated blood products. Horowitz B; Prince AM; Horowitz MS; Watklevicz C Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797 [TBL] [Abstract][Full Text] [Related]
5. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives. Hilfenhaus J; Niedrig M; Nowak T Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794 [TBL] [Abstract][Full Text] [Related]
6. Criteria for the choice of viruses in validation studies. Minor PD Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805 [TBL] [Abstract][Full Text] [Related]
7. Viral inactivation vs biological activity. Barrowcliffe TW Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795 [TBL] [Abstract][Full Text] [Related]
8. Affinity chromatography to remove viruses during preparation of plasma derivatives. Lawrence JE Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803 [TBL] [Abstract][Full Text] [Related]
9. Reducing the risk of infection from plasma products: specific preventative strategies. Burnouf T; Radosevich M Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252 [TBL] [Abstract][Full Text] [Related]
10. Use of bacteriophages as surrogates for mammalian viruses. McAlister M; Aranha H; Larson R Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677 [TBL] [Abstract][Full Text] [Related]
11. [Viral safety considerations in immunoglobulin preparations]. Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262 [No Abstract] [Full Text] [Related]
13. Photochemical inactivation of viruses and bacteriophage in plasma and plasma fractions. Morel P; Lin L; Wiesehahn G; Corash L Blood Cells; 1992; 18(1):27-41; Discussion 41-2. PubMed ID: 1617190 [TBL] [Abstract][Full Text] [Related]
14. Virological issues in the use of cell therapies. Minor PD Dev Biol (Basel); 2004; 118():151-3. PubMed ID: 15645685 [TBL] [Abstract][Full Text] [Related]
15. Chromatographic removal of viruses from plasma derivatives. Burnouf T Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization. Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665 [TBL] [Abstract][Full Text] [Related]
18. Pathogen safety of human C1 esterase inhibitor concentrate. Gröner A; Nowak T; Schäfer W Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956 [TBL] [Abstract][Full Text] [Related]
19. Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet A light. Moroff G; Wagner S; Benade L; Dodd RY Blood Cells; 1992; 18(1):43-54; discussion 54-6. PubMed ID: 1617192 [TBL] [Abstract][Full Text] [Related]
20. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider. Vicari G Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]